<DOC>
	<DOCNO>NCT00910741</DOCNO>
	<brief_summary>The purpose study determine recommend dose NC-6004 accord dose-limiting toxicity ( DLT ) combination Gemcitabine , ass efficacy , safety tolerability .</brief_summary>
	<brief_title>NC-6004 ( Nanoplatin ) Gemcitabine Treat Pancreatic Cancer Asia</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patients chemonaive , advanced pancreatic cancer Nonresectable , histologically cytologically confirm , locally advanced metastatic pancreatic cancer Pulmonary fibrosis interstitial pneumonia Marked pleural effusion ascites Grade 2 Severe drug hypersensitivity Metastasis central nervous system brain</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>Gemcitabine</keyword>
</DOC>